Pharmaceutical Technology

JULY 7, 2025

Akeega has been approved in Europe for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with steroid hormone prednisolone since 2023. J&J is now attempting to widen the drug’s application to patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Labelling

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA

The Checkup by Singlecare

JUNE 17, 2024

When over-the-counter (OTC) remedies don’t cut it, your healthcare provider may prescribe Zofran ( ondansetron ), a medication used to treat upset stomach and prevent vomiting—especially when caused by chemotherapy, radiation therapy, and surgery. It’s also can be used off-label to treat morning sickness during pregnancy.

Chemotherapy

pharmaphorum

SEPTEMBER 7, 2022

The European Commission has approved Tecartus (brexucabtagene autoleucel) for adults aged 26 and over with relapsed or refractory B-cell precursor ALL, a patient population not covered by the label for Novartis’ CD19 CAR-T Kymriah (tisagenlecleucel), which covers paediatric and young adult patients up to age 25.

Labelling

European Pharmaceutical Review

OCTOBER 19, 2023

Additionally, in June 2023, the world’s largest radionuclide production facility of lutetium-177 opened in Germany. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? Recent advancements for radiopharmaceuticals in oncology include a $1.4 Internet] Jaafar-Thiel, L.

Chemotherapy

pharmaphorum

AUGUST 31, 2022

The 345-subject CodeBreaK 200 trial of once-daily Lumakras (sotorasib) met its primary objective of improving progression-free survival (PFS) compared to chemotherapy with intravenous docetaxel in KRAS G12C-mutated NSCLC patients previously treated with platinum-based doublet chemotherapy and checkpoint inhibitor therapy.

Chemotherapy

The Checkup by Singlecare

DECEMBER 13, 2023

Antiemetics may also reduce radiation-associated or chemotherapy-induced nausea resulting from cancer treatment. Be sure to follow the dosing instructions on the label for your child’s age. Antiemetic side effects Most OTC antiemetics are well-tolerated and safe if taken according to the labeled instructions.

Dosage

Hospital Pharmacy Europe

DECEMBER 18, 2023

4,5 Polypharmacy – daily use of five or more drugs – is common in these patients and increases the risk of DRPs, which can result in adverse outcomes such as postoperative complications, chemotherapy toxicities and functional decline. 10,11 This can be due to side effects of chemotherapy or the addition of certain supportive care medications.

Chemotherapy

pharmaphorum

JANUARY 23, 2023

Jazz Pharma’s $325 million gamble on rights to Zymeworks’ HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout at the ASCO-GI 2023 congress. The median progression-free survival (PFS) of 12.5 months, with a median duration of response was 20.4

Chemotherapy

pharmaphorum

DECEMBER 5, 2022

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.

Chemotherapy

Pharmaceutical Technology

JUNE 7, 2023

Known as Pedmark in the US, Pedmarqsi is the first and only therapy to receive approval in the European Union to prevent cisplatin chemotherapy-induced hearing loss (ototoxicity) in patients aged between one month and 18 years with localised, non-metastatic solid tumours.

Chemotherapy

pharmaphorum

DECEMBER 5, 2022

The positive news comes after a challenging time for GSK, marked by the withdrawal of its US marketing approval for multiple myeloma therapy Blenrep (belantamab mafodotin) last month, along with the narrowing of the label for PARP inhibitor Zejula (niraparib), as well as a retreat from the cell therapy category.

Chemotherapy

pharmaphorum

DECEMBER 13, 2022

While the wording on the label is almost the same, Mirati reckons its drug has an efficacy and pharmacodynamic profile that will help it catch up with Lumakras, which brought in $210 million in sales in the first nine months of this year, $75 million of that in the third quarter.

FDA

Hospital Pharmacy Europe

NOVEMBER 6, 2023

Adagrasib is a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

Chemotherapy

The Checkup by Singlecare

OCTOBER 27, 2023

Sources Analysis of reports of unintended pregnancies associated with the combined use of non-enzyme-inducing antibiotics and hormonal contraceptives , British Medical Journal (2020) Oral contraceptive efficacy and antibiotic interaction: a myth debunked , Journal of the American Academy of Dermatology (2002) Treatment of pneumococcal meningitis with (..)

Adverse Reactions

The Checkup by Singlecare

DECEMBER 29, 2023

People with cancer : There is little information about the interactions between CoQ10 and cancer chemotherapy, so healthcare professionals may advise against its use during cancer treatment. Side effects are minimal and experienced in less than 1% of people taking the supplement, according to the drug label.

FDA

ISPE

MAY 10, 2023

SPuMoNI: Enhancing Pharma Data Quality through Smart Technologies Trudy Patterson Wed, 05/10/2023 - 09:25 Features May / June 2023 SPuMoNI: Enhancing Pharma Data Quality through Smart Technologies Mariola Mier David Cerrai, Ph.D. Mexican Governor: Cancer Children Given Water Instead of Chemotherapy.” Chis, Ph.D. 30 June 2016.

Chemotherapy

Hospital Pharmacy Europe

AUGUST 2, 2023

This global, multi-centre, open-label, Phase 3 study, evaluated Trodelvy versus the physician’s choice of chemotherapy (eribulin, capecitabine, gemcitabine or vinorelbine). as assessed by blinded independent central review for participants treated with Trodelvy compared to those treated with chemotherapy.

Chemotherapy

European Pharmaceutical Review

DECEMBER 5, 2022

PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Regulatory approval will be discussed with the US Food and Drug Administration (FDA) in 2023. The PSMAfore study.

Chemotherapy

pharmaphorum

OCTOBER 25, 2021

The European Commission has cleared Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for locally recurrent, unresectable or metastatic TNBC involving tumours with a PD-L1 expression score of 10 or more. months to 23 months, according to data reported at this year’s ESMO cancer conference.

Chemotherapy

pharmaphorum

JUNE 23, 2021

KEYNOTE-826 enrolled 600 patients with both PD-L1-positive and PD-L1-negative tumours who were treated with a regimen of Keytruda and chemotherapy, given either with or without Roche’s Avastin (bevacizumab). The company hasn’t disclosed the data yet, but says it will do so at a future medical meeting.

Chemotherapy

European Pharmaceutical Review

FEBRUARY 13, 2023

About the KarMMa-3 study In the open-label, global, randomised, controlled trial, two-thirds of multiple myeloma patients received ide-cel and one-third received standard care, which consisted of a monoclonal antibody drug, a proteasome inhibitor, or chemotherapy.

Chemotherapy

European Pharmaceutical Review

JANUARY 23, 2023

About the Phase III trial for pancreatic ductal adenocarcinoma NAPOLI 3 is a randomised, open-label Phase III trial of Onivyde treatment regimen (NALIRIFOX) in patients who have not previously received chemotherapy for metastatic pancreatic ductal adenocarcinoma. These data describe the final analysis after acceptance of the abstract.

Chemotherapy

The Thyroid Pharmacist

SEPTEMBER 1, 2023

They include anesthetics, antacids, anti-anxiety medications, antibiotics, antidepressants, antifungals, cholesterol-lowering medications, anti-malarial medications, chemotherapy, appetite suppressants, arthritis medications, psychotropics, and steroids. Accessed August 9, 2023. Accessed August 9, 2023. Accessed August 29, 2023.

Adverse Reactions

The FDA Law Blog

JANUARY 18, 2024

Houck — In August 2023 the Food and Drug Administration (“FDA”) and Health and Human Services (“HHS”) recommended that the Drug Enforcement Administration (“DEA”) reschedule marijuana from schedule I under the federal Controlled Substances Act (“CSA”) to schedule III. chemotherapy-induced), pain, and post-traumatic stress disorder.

FDA

The FDA Law Blog

MAY 5, 2024

29, 2023). FDA/HHS Analysis, 2023 FDA/HHS last conducted an eight-factor analysis of marijuana in 2016 and concluded that marijuana continued to meet schedule I criteria. Unlike its 2016 analysis, FDA’s/HHS’ 2023 analysis considers marijuana to have a currently accepted medical use in treatment in the U.S. Letter to U.S.

Controlled Substances

The Checkup by Singlecare

MAY 8, 2023

Cymbalta is a non-opioid medication and is labeled as an antidepressant, more specifically a serotonin/norepinephrine reuptake inhibitor (SNRI). As of March 2023 , naloxone is now available without a prescription. The post Tramadol (Ultram) alternatives: What can I take instead of tramadol? appeared first on The Checkup.

Controlled Substances

The FDA Law Blog

MAY 21, 2024

29, 2023) (“Basis”); NPRM at 44,603. In 2023, HHS conducted a different approach, a two-part test, to determine whether marijuana has a CAMU. FDA analyzed anorexia related to a medical condition, anxiety, epilepsy, inflammatory bowel disease, chemotherapy-induced nausea and vomiting, pain, and post-traumatic stress disorder.

Controlled Substances

The Thyroid Pharmacist

NOVEMBER 29, 2024

The biggest culprits associated with weight gain include antipsychotic medications which were traditionally developed for schizophrenia, but are used on and off-label for conditions like bipolar disorder, depression, anxiety, irritability, and even insomnia! [17] Published 2023 Aug 6. Published 2023 Apr 13. J Clin Med.

Health and Personal Care Stores